Boston Scientific Corporation

Revenue is anchored by single-use disposables consumed in hospital procedures across cardiology, endoscopy, and urology, with capital equipment placement generating recurring pull-through demand. Procedure volumes showed COVID-related deferral sensitivity in 2020 and unexpected EP and Watchman deceleration beginning in Q1 2026, confirming that revenue is tied to clinical utilization rather than contractually locked.

The Cardiovascular segment represented 66% of FY2025 net sales against 34% for MedSurg, placing segment concentration above the moderate-spread range. Within Cardiovascular, multiple distinct clinical categories (EP, structural heart, cardiac rhythm management, peripheral interventions) partially mitigate this, while MedSurg covering endoscopy and urology provides a materially different demand driver.

The United States represented 64% of FY2025 net sales of $20.1 billion, with EMEA, APAC, and LACA collectively contributing the remaining 36%. The geographic mix is moderately concentrated and leaves earnings materially exposed to changes in US reimbursement policy and hospital group purchasing dynamics.

Boston Scientific's adjusted operating margin reached approximately 28% in Q1 2026, with the company demonstrating improving operating leverage as disposables revenue scaled over FY2021-FY2025. The model is not fully asset-light; a large commercial field force and clinical support infrastructure grow partially in line with volume, but gross margins in the mid-to-high 60s support healthy incremental margins on volume growth.

A large share of BSX revenue is generated through single-use disposables consumed in medically necessary procedures — cardiac ablation, left atrial appendage closure, and endoscopy — providing high repeat-purchase frequency and non-discretionary demand characteristics. Revenue is not contractually subscribed but is mission-critical in clinical settings and reinforced by capital equipment placements and service relationships.